Does UnitedHealthcare Cover Hormone Replacement Therapy?

UnitedHealthcare does cover hormone replacement therapy in most of its plans, but whether your specific treatment is paid for depends on three things: the medical reason for the prescription, the plan you’re enrolled in, and whether the drug is FDA-approved and on your formulary. Testosterone for diagnosed low testosterone, estrogen and progesterone for menopause, and cross-sex hormones for gender dysphoria are each handled under separate rules, and gender-affirming care in particular shifted after a 2025 federal rule change.

Testosterone Replacement for Low Testosterone

UnitedHealthcare covers testosterone replacement across commercial, individual exchange, Medicaid community, and Medicare Advantage plans when a patient has clinically documented hypogonadism. Age-related or “late-onset” low testosterone alone may not clear the bar; UHC’s policy states the safety and efficacy of therapy in that population have not been established.1UHC Provider. Testosterone Replacement Supplementation Therapy – Community Plan

To qualify, you have to meet one of two pathways. The first is a documented medical history of a condition known to cause testosterone deficiency, such as bilateral orchiectomy, panhypopituitarism, or Klinefelter’s syndrome. The second is lab proof: two early-morning blood draws showing serum total testosterone below 300 ng/dL, taken on separate days. If a condition affects sex-hormone binding globulin, a single calculated free testosterone level below 50 pg/mL can substitute. Patients already on therapy need follow-up labs within the past six to twelve months showing levels at or below the normal male range.2UHC Provider. Testosterone Replacement Supplementation Therapy

Preferred products include testosterone cypionate (Depo-Testosterone), testosterone enanthate, testosterone pellets (Testopel), and testosterone undecanoate (Aveed). Non-preferred products like Azmiro can be covered if your doctor documents that a preferred option failed or caused an adverse reaction, though on some plans Azmiro is excluded outright.3UHC Provider. Testosterone Replacement Supplementation Therapy – Individual Exchange

Menopause-Related Hormone Therapy

Coverage for menopausal hormone therapy runs through the pharmacy benefit rather than a dedicated medical policy. UnitedHealthcare’s health information page discusses estrogen, progesterone, and bioidentical options, noting that some bioidentical hormones such as oral progesterone are FDA-approved, and directs members to sign in to check their specific benefits.4UHC. Hormone Replacement Therapy

Whether a specific product is covered, and at what copay, depends on its tier on your plan’s prescription drug list. Estradiol patches, estrogen creams, and combination products like Activella or Bijuva may each sit on different tiers, and drugs can be subject to prior authorization, step therapy, or quantity limits.5UHC Provider. Commercial Prescription Drug List The medication search tool at myuhc.com, or the number on the back of your ID card, is the fastest way to confirm.

For Medicare Advantage members, the formulary is separate. Some commonly prescribed vaginal estrogen products may not appear on the standard Medicare Advantage drug list, but a non-formulary drug can still be covered through an exception request if the prescribing doctor submits a supporting statement.6University of Arkansas System Benefits. Complete Drug List (Formulary)

Gender-Affirming Hormone Therapy

UnitedHealthcare covers gender-affirming hormone therapy for transgender adults in commercial, individual exchange, community, and Medicare Advantage plans, as long as the specific plan document includes coverage for gender dysphoria treatment.7UHC Provider. Gender Dysphoria Treatment Covered services typically include cross-sex hormones, puberty-suppressing medications for adolescents who meet clinical criteria, and lab work to monitor safety.8UHC Provider. Gender Dysphoria Treatment – Community Plan

For adults, UHC requires a diagnosis of gender dysphoria under DSM-5-TR criteria from a mental health professional and a prescription written by or in consultation with an endocrinologist or a provider experienced in transgender hormone therapy. Authorizations last twelve months and must be renewed.2UHC Provider. Testosterone Replacement Supplementation Therapy Prior authorization is generally required, though some plans treat feminizing hormones more leniently than testosterone and puberty blockers.9UHG1. Colorado Exchange Gender Affirming Care Coverage Guide

Not every UnitedHealthcare plan includes this benefit. Nearly twenty states have individual exchange plans that defer to the specific benefit plan document rather than following UHC’s standard gender dysphoria policy, and several Medicaid community plans follow their own state guidelines instead.7UHC Provider. Gender Dysphoria Treatment8UHC Provider. Gender Dysphoria Treatment – Community Plan Reading your Evidence of Coverage, or asking member services, is the only reliable way to know.

The 2026 Rule Change for Marketplace Plans

A federal rule finalized by the Department of Health and Human Services in June 2025 prohibits insurers from covering “specified sex-trait modification procedures” as an Essential Health Benefit under the ACA for the 2026 plan year forward. The rule defines those procedures to include gender-affirming hormone therapy when prescribed to align a person’s body with an identity that differs from their biological sex.10Westlaw. HHS Prohibits Coverage of Gender Affirming Care as ACA Essential Health Benefits

ACA marketplace plans, including UnitedHealthcare’s individual exchange plans, are no longer required to cover gender-affirming hormones as an essential benefit. Plans may still cover them voluntarily, but when the services aren’t classified as EHBs, patients lose cost-sharing protections such as out-of-pocket maximums and protections against annual and lifetime limits on those services.11KFF. New Rule Proposes Changes to ACA Coverage of Gender Affirming Care States that independently mandate the coverage in their benchmark plans must now pay for it themselves; HHS has named California, Colorado, New Mexico, Vermont, and Washington.12SHVS. New Federal Rules Affecting Coverage of Treatment for Gender Dysphoria

Twenty-one states filed suit to block the rule in July 2025. A federal court denied a preliminary injunction, and cross-motions for summary judgment remain pending.13Georgetown Law Litigation Tracker. State of California et al. v. Kennedy et al. The rule applies to individual and small-group marketplace plans only. Large employer-sponsored and self-insured plans aren’t subject to EHB requirements and set their own terms; a 2024 survey cited by KFF found about 24% of large employers cover gender-affirming hormone therapy, rising to 50% among firms with 5,000 or more workers.11KFF. New Rule Proposes Changes to ACA Coverage of Gender Affirming Care

How Medicare Advantage Differs

Original Medicare generally covers the office visits and related care around hormone therapy but not the drugs themselves; the drugs run through Part D or a Medicare Advantage plan’s drug benefit.14Medigap.com. Hormone Replacement Therapy Medicare Coverage For testosterone, there’s no National Coverage Determination, so UHC applies its own evidence-based criteria, and Medicare Advantage members may also need to work through Part B step therapy and check Local Coverage Determinations.2UHC Provider. Testosterone Replacement Supplementation Therapy Cross-sex hormone therapy for gender dysphoria may be covered under Medicare Advantage as well, subject to Part B versus Part D rules.15UHC Provider. Gender Dysphoria Gender Reassignment Surgery – Medicare Advantage

What UnitedHealthcare Will Not Cover

Compounded hormone products are excluded across every UHC plan type. That covers compounded testosterone pellets, compounded estrogen, and compounded progesterone pellets. UHC classifies them as “not proven or medically necessary” because they lack FDA approval.1UHC Provider. Testosterone Replacement Supplementation Therapy – Community Plan The pellet distinction is a common sticking point: FDA-approved Testopel is covered, but pellets prepared by a compounding pharmacy are not.3UHC Provider. Testosterone Replacement Supplementation Therapy – Individual Exchange

If You’re Denied Coverage

You have the right to appeal any denial. For Medicare plans, the first step is a Level 1 appeal, formally a “redetermination,” filed within 65 calendar days of the denial notice. UHC must decide a standard appeal within seven calendar days, or 72 hours for an expedited one. If UHC misses the deadline, the appeal escalates automatically to a Level 2 review by an Independent Review Entity.16UHC. Prescription Drug Appeals

What makes an appeal stronger is documentation from your prescribing doctor explaining why formulary alternatives would be ineffective or harmful. That’s especially important for formulary exceptions and prior authorization denials.17UHC. Appeals Grievances Process While the appeal is pending, ask about a one-time temporary supply of the medication. Medicare Part D appeals can be sent to the Medicare Part D Appeals and Grievance Department, P.O. Box 6106, M/S CA 124-0197, Cypress, CA 90630, or faxed to 1-866-308-6294.16UHC. Prescription Drug Appeals Commercial and exchange plans have their own appeal procedures; check your Evidence of Coverage or call the number on your ID card.